Treatments and limitations for methicillin-resistant Staphylococcus aureus: A review of current literature

Treatments and limitations for methicillin-resistant Staphylococcus aureus: A review of current literature

[1]  K. Nakanishi,et al.  A successful salvage therapy with daptomycin and linezolid for right-sided infective endocarditis and septic pulmonary embolism caused by methicillin-resistant Staphylococcus aureus. , 2018, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  J. Ruiz,et al.  Vancomycin and daptomycin minimum inhibitory concentrations as a predictor of outcome of methicillin-resistant Staphylococcus aureus bacteraemia. , 2018, Journal of global antimicrobial resistance.

[3]  Charles E. Leonard,et al.  Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug‐outcome associations: The case of clindamycin and Clostridium difficile infection , 2018, Pharmacoepidemiology and drug safety.

[4]  S. Hashemian,et al.  Linezolid: a review of its properties, function, and use in critical care , 2018, Drug design, development and therapy.

[5]  Pei-Chi Hsu,et al.  Effect of a Point Mutation in mprF on Susceptibility to Daptomycin, Vancomycin, and Oxacillin in an MRSA Clinical Strain , 2018, Front. Microbiol..

[6]  Kimmoonsuk,et al.  Emergence of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Clinical Isolates Among Daptomycin-Naive Patients in Korea. , 2017 .

[7]  P. Linden,et al.  Incidence, prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management and treatment , 2017, Critical Care.

[8]  B. Werth.  Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis , 2017, The Journal of antimicrobial chemotherapy.

[9]  Jennifer A. Johnson,et al.  Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review , 2017, Open forum infectious diseases.

[10]  S. Jimi,et al.  Increased drug resistance of meticillin-resistant Staphylococcus aureus biofilms formed on a mouse dermal chip model , 2017, Journal of medical microbiology.

[11]  D. Mould,et al.  A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug-Drug Interaction. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  P. Cavaco-Silva,et al.  Susceptibility patterns of Staphylococcus aureus biofilms in diabetic foot infections , 2016, BMC Microbiology.

[13]  D. Karras,et al.  A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Holubar,et al.  Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches. , 2016, Infectious disease clinics of North America.

[15]  D. Missiakas,et al.  Pathogenesis of Staphylococcus aureus Bloodstream Infections. , 2016, Annual review of pathology.

[16]  S. Mansy,et al.  EFFECT OF LINEZOLID ALONE AND IN COMBINATION WITH OTHER ANTIBIOTICS, ON METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS. , 2016, Journal of the Egyptian Society of Parasitology.

[17]  K. Kishor,et al.  Linezolid Induced Adverse Drug Reactions - An Update. , 2015, Current drug metabolism.

[18]  G. Stein,et al.  Oritavancin: A Long-Half-Life Lipoglycopeptide. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  E. Clementi,et al.  Prolonged inductive effect of rifampicin on linezolid exposure , 2015, European Journal of Clinical Pharmacology.

[20]  H. Maples,et al.  Balancing Vancomycin Efficacy and Nephrotoxicity: Should We Be Aiming for Trough or AUC/MIC? , 2015, Pediatric Drugs.

[21]  A. Saitoh,et al.  High rate of inducible clindamycin resistance in Staphylococcus aureus isolates--a multicenter study in Tokyo, Japan. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[22]  G. Sakoulas,et al.  Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. , 2014, Clinical therapeutics.

[23]  V. Fowler,et al.  Clinical management of Staphylococcus aureus bacteremia: a review. , 2014, JAMA.

[24]  Eric Caumes,et al.  Emergence of trimethoprim resistance gene dfrG in Staphylococcus aureus causing human infection and colonization in sub-Saharan Africa and its import to Europe. , 2014, The Journal of antimicrobial chemotherapy.

[25]  T. Takata,et al.  Linezolid minimum inhibitory concentration (MIC) creep in methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates at a single Japanese center. , 2014, Biological & pharmaceutical bulletin.

[26]  S. Kim.  Is Therapeutic Drug Monitoring of Teicoplanin Useful? , 2014, Infection & chemotherapy.

[27]  F. Otsuka,et al.  Successful treatment of persistent MRSA bacteremia using high-dose daptomycin combined with rifampicin. , 2014, Internal medicine.

[28]  G. Corey,et al.  Methicillin-resistant Staphylococcus aureus: an evolving pathogen. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  S. Baliga,et al.  Nosocomial Infections and Drug Susceptibility Patterns in Methicillin Sensitive and Methicillin Resistant Staphylococcus aureus. , 2013, Journal of clinical and diagnostic research : JCDR.

[30]  M. H. Ensom,et al.  Addition of Rifampin to Vancomycin for Methicillin-Resistant Staphylococcus aureus Infections: What Is the Evidence? , 2013, The Annals of pharmacotherapy.

[31]  S. Atmaca,et al.  Assessment of methicillin and clindamycin resistance patterns in Staphylococcus aureus isolated from a tertiary hospital in Turkey. , 2013, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.

[32]  D. Maki,et al.  Relationship of In Vitro Synergy and Treatment Outcome with Daptomycin plus Rifampin in Patients with Invasive Methicillin-Resistant Staphylococcus aureus Infections , 2013, Antimicrobial Agents and Chemotherapy.

[33]  J. Hernández-Quero,et al.  Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm. , 2012, The Journal of antimicrobial chemotherapy.

[34]  L. Schulz,et al.  Addition of Ceftaroline to Daptomycin after Emergence of Daptomycin-Nonsusceptible Staphylococcus aureus during Therapy Improves Antibacterial Activity , 2012, Antimicrobial Agents and Chemotherapy.

[35]  Á. Soriano,et al.  Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections , 2012, Scandinavian journal of infectious diseases.

[36]  A. Bettencourt,et al.  Daptomycin: a review of properties, clinical use, drug delivery and resistance. , 2012, Mini reviews in medicinal chemistry.

[37]  O. Yang,et al.  Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. , 2011, Diagnostic microbiology and infectious disease.

[38]  V. Nizet,et al.  Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  C. Cabellos,et al.  Efficacy of Usual and High Doses of Daptomycin in Combination with Rifampin versus Alternative Therapies in Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.

[41]  Hien M. Nguyen,et al.  Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? , 2010, The Journal of antimicrobial chemotherapy.

[42]  Ronald N. Jones,et al.  Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. , 2009, The Journal of antimicrobial chemotherapy.

[43]  S. Deresinski.  Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  T. Fujino,et al.  MRSA tricuspid valve infective endocarditis with multiple embolic lung abscesses treated by combination therapy of vancomycin, rifampicin, and sulfamethoxazole/trimethoprim. , 2009, Journal of cardiology.

[45]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[46]  M. Beuran,et al.  Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. , 2008, The Journal of antimicrobial chemotherapy.

[47]  M. Rybak,et al.  Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations , 2008, Antimicrobial Agents and Chemotherapy.

[48]  L. Miller,et al.  Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. , 2008, Archives of internal medicine.

[49]  S. Deresinski.  Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  P. Appelbaum,et al.  Activity of Daptomycin Alone and in Combination with Rifampin and Gentamicin against Staphylococcus aureus Assessed by Time-Kill Methodology , 2007, Antimicrobial Agents and Chemotherapy.

[51]  Guiqing Wang,et al.  Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year Period , 2006, Journal of Clinical Microbiology.

[52]  Michael J. Rybak,et al.  Tigecycline: First of a New Class of Antimicrobial Agents , 2006, Pharmacotherapy.

[53]  B. Murphy,et al.  Rhabdomyolysis during therapy with daptomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  V. Fowler,et al.  Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. , 2004, The Journal of infectious diseases.

[55]  D R Allington,et al.  Quinupristin/dalfopristin: a therapeutic review. , 2001, Clinical therapeutics.